Recombinant CPA1 antibody (full length)

Catalog No. ABIN7877791

The Rabbit Monoclonal anti-CPA1 antibody (Clone CPA1-9622R) (ABIN7877791) specifically detects CPA1 in IHC (p). The antibody is reactive with Human samples.

Quick Overview for Recombinant CPA1 antibody (full length) (ABIN7877791)

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This CPA1 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: CPA1-9622R

Product Details anti-CPA1 Antibody

Binding Specificity: full length

Purpose: Recombinant Carboxypeptidase A1 Antibody / CPA1

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human CPA1 protein was used as the immunogen for the recombinant Carboxypeptidase A1 antibody.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal dilution of the recombinant Carboxypeptidase A1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the recombinant Carboxypeptidase A1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for CPA1

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Alternative Name: Carboxypeptidase A1

Background: Human pancreatic procarboxypeptidase A exists as three different active forms, two of which are designated carboxypeptidase A1 (CPA1) and carboxypeptidase A2 (CPA2). CPA1, also known as CPA, is a 419 amino acid secreted monomeric protein that is highly expressed in pancreatic tissue. Functioning as a pancreatic exopeptidase, CPA1 uses zinc as a cofactor to catalyze the release of C-terminal amino acids from a variety of proteins, thereby playing a key role in protein digestion and degradation. Via its catalytic activity, CPA1 is also thought to be involved in zymogen (proenzyme) inhibition, probably functioning to block enzyme activation pathways. Abnormal levels of CPA1 are associated with pancreatic cancer, suggesting a possible role in either tumor progression or tumor suppression events.

UniProt: P15085